This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-21. (cancelled)

22. (currently amended) A method of increasing glucose uptake by skeletal muscle of a patient, comprising administering ~~a~~ at least one phosphodiesterase antagonist selected from the group consisting of vinpocetine, zaprinast and dipyridamole, sildenafil, theophylline, aminophylline, isobutylmethyl xanthine anagrelide, tadalafil, dyphylline, vardenafil, caffeine, milrinone, amrinone pimobendan, cilostamide, enoximone, teroximone, vesmarinone, rolipram and R020-1724.

23-49. (cancelled)

50. (currently amended) The method of claim ~~claims~~ 22, wherein the phosphodiesterase antagonist is of at least one of phosphodiesterase subtype 3 or subtype 5.

51. (cancelled)

52. (previously presented) The method of claim 22, wherein the phosphodiesterase antagonist is administered by intravenous administration.

53. (cancelled)

54. (previously presented) The method of claim 22, wherein the phosphodiesterase antagonist is administered by transdermal administration.

55-57. (cancelled)

58. (previously presented) The method of claim 22, wherein the phosphodiesterase antagonist is administered by intra peritoneal administration.

59. (cancelled)

60. (previously presented) The method of claim 22, wherein the phosphodiesterase antagonist is administered by portal vein injection.

61. (cancelled)

62. (previously presented) The method of claim 22, wherein the phosphodiesterase antagonist is administered orally at a dose of between about 2 and 300 mg/kg body weight.

63. (cancelled)

64. (previously presented) The method of claim 22, wherein the phosphodiesterase antagonist is administered intravenously at a dose of between about 5 and 500 μg/kg body weight.